HUP0001319A2 - Heteroaril-hexanolsav-amid származékok, azok előállítása és szelektív inhibitorokként történő alkalmazása az MIP-1alfa saját CCR1 receptoraihoz való kapcsolódásának megakadályozására - Google Patents

Heteroaril-hexanolsav-amid származékok, azok előállítása és szelektív inhibitorokként történő alkalmazása az MIP-1alfa saját CCR1 receptoraihoz való kapcsolódásának megakadályozására

Info

Publication number
HUP0001319A2
HUP0001319A2 HU0001319A HUP0001319A HUP0001319A2 HU P0001319 A2 HUP0001319 A2 HU P0001319A2 HU 0001319 A HU0001319 A HU 0001319A HU P0001319 A HUP0001319 A HU P0001319A HU P0001319 A2 HUP0001319 A2 HU P0001319A2
Authority
HU
Hungary
Prior art keywords
group
heteroaryl
optionally substituted
carbon atoms
atom
Prior art date
Application number
HU0001319A
Other languages
English (en)
Inventor
Matthew Frank Brown
John Charles Kath
Christopher Stanley Poss
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0001319A2 publication Critical patent/HUP0001319A2/hu
Publication of HUP0001319A3 publication Critical patent/HUP0001319A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

A jelen találmány tárgyát azok az új, (I) általános képletű vegyületekképezik, ahol a képletben R1 jelentése adott esetben helyettesített 2-9 szénatomszámúheteroarilcsoport; R2 jelentése adott esetben helyettesített fenil-(CH2)m- csoport,naftil-(CH2)m- csoport, (3-10 szénatomszámú cikloalkil)-(CH2)m-csoport, 1-6 szénatomszámú alkilcsoport vagy 2-9 szénatomszámúheteroaril-(CH2)m- csoport, ahol az m paraméter értéke 0 és 4 közöttiegész szám; R3 jelentése hidrogénatom vagy adott esetben helyettesített 1-10szénatomszámú alkilcsoport, (3-10 szénatomszámú cikloalkil)-(CH2)n-csoport, 2-9 szénatomszámú heterocikloalkil-(CH2)n- csoport, 2-9szénatomszámú heteroaril-(CH2)n- csoport vagy aril-(CH2)n- csoport,ahol az n paraméter értéke 0 és 6 közötti egész szám; vagy az R3 és aszénatom, amelyhez kapcsolódik, adott esetben helyettesített és/vagyegy 5-7 tagú karbociklusos gyűrűvel fuzionált; R4 jelentése hidrogénatom, 1-6 szénatomszámú alkilcsoport,hidroxicsoport, 1-6 szénatomszámú alkoxicsoport, hidroxi-(1-6szénatomszámú alkil)-csoport, 1-6 szénatomszámú alkoxi-(C=O)- csoport,(3-10 szénatomszámú cikloalkil)-(CH2)p- csoport vagy adott esetbenhelyettesített 2-9 szénatomszámú heterocikloalkil-(CH2)p- csoport, 2-9szénatomszámú heteroaril-(CH2)p-csoport, fenil-(CH2)p- csoport vagynaftil-(CH2)p- csoport, ahol a p paraméter értéke 0 és 4 közötti egészszám; vagy az R4 és R5 csoportok azzal a nitrogénatommal együtt,amelyhez kapcsolódnak, adott esetben helyettesített 2-9 szénatomszámúheterocikloalkilcsoportot képeznek; R5 jelentése hidrogénatom, 1-6 szénatomszámú alkilcsoport vagyaminocsoport. A jelen találmány tárgyát képező vegyületek potenciálisés szelektív inhibitorai az MIP-1a saját CCR1-receptorához valókapcsolódásának és ezért alkalmasak a gyulladások és egyébimmunbetegségek kezelésére. Ó
HU0001319A 1997-02-26 1998-02-05 Heteroaryl carboxylic amide derivatives and pharmaceutical compositions containing them HUP0001319A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3916997P 1997-02-26 1997-02-26
PCT/US1998/001568 WO1998038167A1 (en) 1997-02-26 1998-02-05 Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor

Publications (2)

Publication Number Publication Date
HUP0001319A2 true HUP0001319A2 (hu) 2001-04-28
HUP0001319A3 HUP0001319A3 (en) 2002-01-28

Family

ID=21904033

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001319A HUP0001319A3 (en) 1997-02-26 1998-02-05 Heteroaryl carboxylic amide derivatives and pharmaceutical compositions containing them

Country Status (40)

Country Link
US (1) US6403587B1 (hu)
EP (1) EP0966443B1 (hu)
JP (1) JP3771591B2 (hu)
KR (1) KR100447553B1 (hu)
CN (1) CN1248968A (hu)
AP (1) AP1056A (hu)
AR (1) AR011168A1 (hu)
AT (1) ATE421954T1 (hu)
AU (1) AU745687B2 (hu)
BG (1) BG103688A (hu)
BR (1) BR9807858A (hu)
CA (1) CA2282834C (hu)
DE (1) DE69840519D1 (hu)
DK (1) DK0966443T3 (hu)
DZ (1) DZ2439A1 (hu)
EA (1) EA002146B1 (hu)
ES (1) ES2319700T3 (hu)
GT (1) GT199800042A (hu)
HN (1) HN1998000035A (hu)
HR (1) HRP980103A2 (hu)
HU (1) HUP0001319A3 (hu)
ID (1) ID23789A (hu)
IL (1) IL131163A (hu)
IS (1) IS5139A (hu)
MA (1) MA24488A1 (hu)
MY (1) MY121294A (hu)
NO (1) NO313877B1 (hu)
NZ (1) NZ336629A (hu)
OA (1) OA11090A (hu)
PA (1) PA8447801A1 (hu)
PE (1) PE59099A1 (hu)
PL (1) PL335484A1 (hu)
SK (1) SK112899A3 (hu)
TN (1) TNSN98036A1 (hu)
TR (1) TR199902056T2 (hu)
UA (1) UA67735C2 (hu)
UY (1) UY24908A1 (hu)
WO (1) WO1998038167A1 (hu)
YU (1) YU41399A (hu)
ZA (1) ZA981602B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO1999025686A1 (en) 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs
US6673801B1 (en) * 1998-02-05 2004-01-06 Pfizer Inc. Dihydroxyhexanoic acid derivatives
CZ20012502A3 (cs) * 1999-01-13 2002-03-13 Millennium Pharmaceuticals, Inc. Funkcionalizované heterocykly jako modulátory chemokinových receptorů
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
JP2002535358A (ja) * 1999-01-29 2002-10-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 移植片拒絶反応及び虚血−再灌流障害の予防方法
US6361979B1 (en) * 1999-02-12 2002-03-26 Pfizer Inc. Microbial conversion of 2-methylquinoxaline
CA2373942A1 (en) 1999-05-18 2000-11-23 Teijin Limited Remedies or prophylactis for diseases in association with chemokines
KR100667645B1 (ko) 1999-08-04 2007-02-28 데이진 가부시키가이샤 환상 아민 ｃｃｒ3 길항제
KR20020072304A (ko) 2000-02-04 2002-09-14 화이자 프로덕츠 인코포레이티드 헤테로사이클릭 아미드 유도체
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
CA2401749A1 (en) * 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6693134B2 (en) * 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
WO2003000238A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
US6982264B2 (en) * 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
TW200304374A (en) * 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
EP1503999A1 (en) * 2002-05-14 2005-02-09 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
ES2333318T3 (es) 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
OA12894A (en) * 2002-08-12 2006-10-13 Pfizer Prod Inc Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide.
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
SI1569907T1 (sl) 2002-12-13 2016-06-30 Ym Biosciences Australia Pty Ltd Na nikotinamidu osnovani kinazni inhibitorji
WO2004054977A1 (en) * 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
AU2003291839B2 (en) * 2002-12-13 2009-01-22 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
WO2005040142A1 (en) * 2003-10-24 2005-05-06 Aventis Pharmaceuticals Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
CA2656079C (en) * 2006-06-23 2012-08-28 Daiichi Sankyo Company, Limited Cyclic amine compound
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
EP0364493A1 (en) 1987-08-07 1990-04-25 The Upjohn Company Renin inhibiting peptides with nonpeptide linkages
IL88619A0 (en) 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
US4923864A (en) 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
EP0374098A3 (de) * 1988-12-15 1991-05-02 Ciba-Geigy Ag Retrovirale Proteasehemmer
JPH06506463A (ja) 1991-04-04 1994-07-21 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルスの治療に有用な化合物
IE922316A1 (en) * 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
WO1993017003A1 (en) 1992-02-26 1993-09-02 Smithkline Beecham Corporation Retroviral protease inhibitors
JPH08501042A (ja) 1992-05-27 1996-02-06 コナグラ インコーポレイテッド 加圧塗布コーティングを有する食品トレイ等
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
DK0708085T3 (da) 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere

Also Published As

Publication number Publication date
AR011168A1 (es) 2000-08-02
UY24908A1 (es) 2000-12-29
SK112899A3 (en) 2001-05-10
HN1998000035A (es) 1999-02-09
TR199902056T2 (xx) 2000-01-21
ATE421954T1 (de) 2009-02-15
HRP980103A2 (en) 1998-12-31
DE69840519D1 (de) 2009-03-19
KR100447553B1 (ko) 2004-09-08
NO994101L (no) 1999-08-25
AP1056A (en) 2002-04-05
CA2282834C (en) 2004-10-05
ZA981602B (en) 1999-09-21
EP0966443A1 (en) 1999-12-29
IL131163A (en) 2005-06-19
OA11090A (en) 2002-03-15
NO994101D0 (no) 1999-08-25
AU6135498A (en) 1998-09-18
YU41399A (sh) 2001-09-28
IS5139A (is) 1999-07-30
UA67735C2 (uk) 2004-07-15
MY121294A (en) 2006-01-28
NZ336629A (en) 2002-11-26
ID23789A (id) 2000-05-11
MA24488A1 (fr) 1998-10-01
BR9807858A (pt) 2000-02-22
JP2000513740A (ja) 2000-10-17
DZ2439A1 (fr) 2003-01-11
EA002146B1 (ru) 2001-12-24
HUP0001319A3 (en) 2002-01-28
ES2319700T3 (es) 2009-05-11
NO313877B1 (no) 2002-12-16
CN1248968A (zh) 2000-03-29
PE59099A1 (es) 1999-06-21
BG103688A (bg) 2000-11-30
PL335484A1 (en) 2000-04-25
EP0966443B1 (en) 2009-01-28
TNSN98036A1 (fr) 2005-03-15
WO1998038167A1 (en) 1998-09-03
KR20000075719A (ko) 2000-12-26
EA199900678A1 (ru) 2000-04-24
JP3771591B2 (ja) 2006-04-26
CA2282834A1 (en) 1998-09-03
IL131163A0 (en) 2001-01-28
PA8447801A1 (es) 2000-05-24
US6403587B1 (en) 2002-06-11
AU745687B2 (en) 2002-03-28
GT199800042A (es) 1999-08-17
DK0966443T3 (da) 2009-03-09

Similar Documents

Publication Publication Date Title
HUP0001319A2 (hu) Heteroaril-hexanolsav-amid származékok, azok előállítása és szelektív inhibitorokként történő alkalmazása az MIP-1alfa saját CCR1 receptoraihoz való kapcsolódásának megakadályozására
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
HUP9903971A1 (hu) Izoflavonok alkalmazása klimax elleni gyógyszerkészítmények előállítására
EA200400892A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
FI931370A (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001122A1 (ru) Ингибиторы синтазы оксида азота
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
EA199900632A1 (ru) 2-амино-6-(2-замещенные-4-фенокси)-замещенные-пиридины
EA200501615A1 (ru) (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов
BR0308780A (pt) Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica
HUP0402076A2 (hu) Szubsztituált indolok, eljárás az előállításukra és fájdalomcsillapítókénti alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES2077623T3 (es) Derivados de isatina, su preparacion y uso.
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
BR0107823A (pt) Processo para a obtenção de ácido fórmico anidro ou substancialmente anidro, uso de uma carboxamida, e, aparelho para realizar um processo